Supplementary material: Questionnaire for the Survey for the implementation of Action Point 1.2 of the 2016–2020 TATFAR Action Plan: publication of a review of antibiotic reduction goals in human medicine from TATFAR partner countries.

This supplementary material is hosted by Eurosurveillance as supporting information alongside the article "Targets for the reduction of the use of antibiotic use in humans in the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) partner countries" on behalf of the authors who remain responsible for the accuracy and appropriateness of the content. The same standards for ethics, copyright, attributions and permissions as for the article apply. Eurosurveillance is not responsible for the maintenance of any links or email addresses provided therein.

## Survey for the implementation of Action Point 1.2 of the 2016-2020 TATFAR Action Plan: publication of a review of antibiotic reduction goals in human medicine from TATFAR partner countries

1.	Has your co	as your country established targets to reduce the use of antibiotics?						
	Yes	No						
2.	If yes (if yo	If yes (if you replied 'No' to Question 1 please move on to Question 3)						
		Are reduction targets for antibiotic use part of a broader national or regional antibiotic resistance strategy or action plan?						
	Yes	No						
		please briefly describe the strategy or action plan, and attach the complete strategy or links to it.						
		describe the targets and the rationale, baseline numbers and the timeline for ing them. $\label{eq:condition}$	le, baseline numbers and the timeline for					
	2.3 Are the targets different for the following:							
	2.3.1	Various healthcare settings (ex. ambulatory care, hospital care, long-term care):						
		Yes No						
		If yes, please describe how and why these targets were established for each specific setting, as appropriate.						
	2.3.2	Different health specialties (ex. paediatrics, geriatrics, dentistry, oncology, orthopaedics):						
		Yes No						
		If yes, please describe how and why these targets were established for each relevant health speciality.						
	2.3.3	All antibiotics or specific antibiotics:						
		Yes No						
		If yes, please describe how and why these targets were established						
	2.3.4	Specific syndrome or infection:						
		Yes No						
		If yes, please describe how and why these targets were established for each syndrome	,					

or infection, as appropriate.

	2.4 How is progress in achieving the above targets monitored and what data have already been collected?								
	2.4.1	Please describe.							
	2.4.2	Are the data publically available?							
		Yes No							
		If yes, please provide links to the relevant documents/publications or attach them to your response.							
	2.5 Please describe the progress in achieving the set targets.								
	2.6 Do the results to date indicate the need to adjust the targets?								
	Ye	es No							
	If yes, please detail.								
3	If you replied No to Question 1								
	3.1 Are discussions being held or plans being developed to introduce targets?								
	-	Yes No							
	If yes, are you able share any preliminary information?								

**TABLE S1.** Links to additional reference material on antibiotic reduction goals and strategies provided by some of the participating countries, TATFAR survey, 2017

	Wasita				
Country	Website				
Belgium	http://organesdeconcertation.sante.belgique.be/fr/organe-d%27avis-et-de-				
	concertation/commissions/bapcoc				
Bulgaria	http://ncipd.org/index.php?option=com_k2&view=item&id=311:kragla-masa-natzionalna-				
	programa-za-ratzionalna-upotreba-na-abtibiotitzite-i-nadzor-na-antimikrobnata-rezistentnost-				
	amr-v-balgariya-proekt⟨=bg				
Finland	http://urn.fi/URN:ISBN:978-952-00-3955-4				
France	http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Evolution-des-				
	consommations-d-antibiotiques-en-France-entre-2000-et-2015-Point-d-Information				
	https://www.ameli.fr/sites/default/files/Documents/5048/document/memo-				
	antibiotherapie assurance-maladie.pdf				
	https://www.ameli.fr/medecin/textes-reference/convention				
	http://invs.santepubliquefrance.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-				
	infectieuses/2017/Surveillance-de-la-consommation-des-antibiotiques				
Italy	http://www.salute.gov.it/imgs/C_17_pubblicazioni_2660_allegato.pdf				
Norway	https://unn.no/fag-og-forskning/norm-norsk-overvakingssystem-for-antibiotikaresistens-hos-				
	<u>mikrober</u>				
	http://www.norgeshelsa.no/norgeshelsa/				
	https://helsenorge.no/Kvalitetsindikatorer/legemidler				
	https://www.regjeringen.no/contentassets/5eaf66ac392143b3b2054aed90b85210/antibiotic-				
Clavaria	resistance-engelsk-lavopploslig-versjon-for-nett-10-09-15.pdf				
Slovenia	http://www.si-map.org/Simap.htm				
Sweden	http://www.government.se/49bbcf/contentassets/168838e186de455ca7fe868bee92d209/swedi				
	sh-strategy-to-combat-antibiotic-resistance.pdf				
	http://strama.se/wp-content/uploads/2016/04/Stramas-mal-for-antibiotikaanvandningen-				
	<u>beskrivning.pdf</u> http://strama.se/?lang=en				
	https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistikdatabaser-och-				
	visualisering/antibiotikastatistik/sverige/				
	https://www.folkhalsomyndigheten.se/publicerat-material/publikationsarkiv/s/swedres-svarm-				
	2016/				
	https://www.folkhalsomyndigheten.se/publicerat-material/publikationsarkiv/s/Swedres-Svarm-				
	2015				
	https://skl.se/tjanster/englishpages/activities/primarycarequality.10073.html				
	http://www.inera.se/infektionsverktyget				
UK	https://fingertips.phe.org.uk/profile/amr-local-indicators				
O.K	https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/570276/ESPAU				
	R executive summary and recommendations.pdf				
	https://www.gov.uk/government/speeches/g7-2016-in-japan-pm-press-statement				
	http://www.gov.scot/Topics/Health/Services/Preventing-Healthcare-				
	Infections/SARHAI5YrStrategicFramework				
	www.scottishmedicines.org.uk/files/sapg/ScotMARAP2 final.pdf				
	http://www.gov.scot/Topics/Health/Services/Preventing-Healthcare-Infections/Infection-				
	Monitoring/SARHAI				
	https://www.scottishmedicines.org.uk/SAPG				
	http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=28418				
	https://www.health-ni.gov.uk/publications/antimicrobial-resistance-guidelines-and-strategy				
US	https://www.cdc.gov/nchs/ahcd/index.htm				
Canada	https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/tackling-				
	antimicrobial-resistance-use-pan-canadian-framework-action.html				

TATFAR: Transatlantic Taskforce on Antimicrobial Resistance; UK: United Kingdom; US: United States.